Knight Therapeutics

Knight Therapeutics Announces Launch of Minjuvi® in Brazil

Retrieved on: 
Thursday, February 29, 2024
ANVISA, DCR, Knight Therapeutics, TSX, DLBCL, GUD, Therapy, Health, Non-Hodgkin lymphoma, Patient, ASCT, Lenalidomide, Knight, Resolution

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.

Key Points: 
  • MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda.
  • Additionally, in October 2023, Knight received pricing approval for Minjuvi® from the Drugs Market Regulation Chamber (“CMED”).
  • “In line with Knight’s commitment to advancing healthcare in Latin America, we are excited to launch Minjuvi in Brazil, an innovative treatment option for addressing a current unmet medical need,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team in Brazil is thrilled to make Minjuvi® available to health care professionals and centers, improving DLBCL patient care in the country,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203

Retrieved on: 
Tuesday, February 27, 2024
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Knight Therapeutics, PD, Zambon, LD, Food, European, Patient, Family, Medication, Neurology, Pharmaceutical industry

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group (“Zambon”), for IPX203 in the European Union, United Kingdom, and Switzerland.
  • Zambon will seek regulatory approval and commercialize IPX203 in Europe.
  • Today’s announcement of a licensing agreement with a European partner is part of Amneal’s broader strategy to bring IPX203 to Parkinson’s patients around the world.
  • Earlier this year, Amneal also signed a license agreement with Knight Therapeutics Inc. granting exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America.

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024
Patient, Knight Therapeutics, Agency, CADTH, Endo International, OTC, Epilepsy, Pharmaceutical industry

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024
Patient, Knight Therapeutics, Agency, CADTH, Endo International, OTC, Epilepsy, Pharmaceutical industry

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil

Retrieved on: 
Monday, October 16, 2023
ANVISA, Physician, TSX, Knight Therapeutics, ORR, Resolution, ASCT, Disease, GUD, Patient, Therapy, B-cell lymphoma, Knight, DCR, Tafasitamab, Paulo, DLBCL, Lenalidomide, CR, Pharmaceutical industry

As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.

Key Points: 
  • As a result, Knight expects to launch Minjuvi® in Brazil in the second quarter of 2024.
  • “We’re excited to continue to advance the approval of Minjuvi® in Brazil, a new treatment option for a current unmet need.
  • We look forward to launching Minjuvi® in Brazil and obtaining approval in other key markets in Latin America,” said Samira Sakhia, Knight Therapeutics President and CEO.
  • “Knight’s team is working diligently with physicians, key institutions and payors to ensure patients have access to Minjuvi®,” said Cristiane Coelho, Knight Therapeutics Brazil General Manager.

Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada

Retrieved on: 
Thursday, June 29, 2023
Knight Therapeutics, Epilepsy, Seizure, Endo, Health Canada, Corona Labs Inc., OTC, Endo International, Pharmaceutical industry, Paladin

DUBLIN and MONTREAL, June 29, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

Key Points: 
  • DUBLIN and MONTREAL, June 29, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "Many adults with partial-onset seizures are not able to control their seizures, even with the availability of many anti-seizure medications," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "Paladin is dedicated to addressing unmet medical needs, and we are proud to achieve this approval—a milestone in epilepsy treatment."
  • Paladin Labs expects to launch XCOPRI™ in December 2023.

Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada

Retrieved on: 
Thursday, June 29, 2023
Knight Therapeutics, Epilepsy, Seizure, Endo, Health Canada, Corona Labs Inc., OTC, Endo International, Pharmaceutical industry, Paladin

DUBLIN and MONTREAL, June 29, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

Key Points: 
  • DUBLIN and MONTREAL, June 29, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada's approval of XCOPRI™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "Many adults with partial-onset seizures are not able to control their seizures, even with the availability of many anti-seizure medications," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "Paladin is dedicated to addressing unmet medical needs, and we are proud to achieve this approval—a milestone in epilepsy treatment."
  • Paladin Labs expects to launch XCOPRI™ in December 2023.

Canada's financial leaders to meet in Quebec City for FEI Canada's Annual Conference, The Face of Change, May 31 to June 2

Retrieved on: 
Wednesday, May 24, 2023
Republican Conference Chair, Learning, Interim, International, Face the Change, Senior, CPA Canada, Financial Executives International, Knight Therapeutics, National Conference, Woman, Human, Canadian Women's Foundation, Youth Challenge International (Canada), CFOS, Asset allocation, Intact Financial, Cirque du Soleil, UKG, Sustainability, Interim management, Face, CFO, Region, CGI, Conference, HCM, Scotiabank, Management, Accedian

Canada's financial leaders to meet in Quebec City for FEI Canada's Annual Conference, The Face of Change.

Key Points: 
  • Canada's financial leaders to meet in Quebec City for FEI Canada's Annual Conference, The Face of Change.
  • This year's theme is "The Face of Change" and highlights the accelerating pace of change with which all financial executives are confronted with daily.
  • Topics include sustainability, governance, pivoting in a changing economy, women in leadership, economic outlook, and mastering self-leadership for professional success.
  • We'd like to invite Canadian CFOs and senior financial executives to apply to become an FEI Canada member.

Alimera Sciences Announces 2022 Financial Results and Business Update

Retrieved on: 
Friday, March 31, 2023
Protocol, Czech Republic, Knight Therapeutics, Pharmacy, Alimera Sciences, Fluocinolone acetonide, Sale, Intravitreal implants, Self-Strengthening Movement, Knight, Injection, Euro, Patient, Observation, Physician, Uveitis, Growth, Therapy, Conference, Cryptocurrency, Pharmaceutical industry, Security (finance), Management, Video game, Trosia

ATLANTA, March 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for 2022.

Key Points: 
  • • 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021
    ATLANTA, March 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for 2022.
  • 2022 product revenue increased 13% to $54.1 million despite negative impact of foreign currency fluctuations in our international segment of $2.4 million.
  • Net revenue decreased by approximately $4.9 million, or 8%, to approximately $54.1 million for 2022, compared to approximately $59.0 million for 2021.
  • All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call.

SPharm Celebrates a Quarter of a Century of Regulatory Affairs Excellence

Retrieved on: 
Wednesday, December 7, 2022
Neurology, Regulatory affairs, Master of Science, Biotechnology, Microbiology, Dentistry, Heart, CTAS, Endocrinology, Cardiology, SPHARM-PDM, Knight Therapeutics, MBA, Plasma, Common Technical Document, Metabolism, Gastroenterology, Rheumatology, Health Canada, Pharmaceutical industry, Operation, MD

VAL-D’OR, Quebec, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SPharm Inc., one of Canada’s top health products regulatory affairs consulting firms, proudly celebrates 25 years of Regulatory Affairs excellence.

Key Points: 
  • VAL-D’OR, Quebec, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SPharm Inc., one of Canada’s top health products regulatory affairs consulting firms, proudly celebrates 25 years of Regulatory Affairs excellence.
  • SPharm is considered a key provider of regulatory intelligence services to clients in both Canada and around the globe, in a broad range of therapeutic areas.
  • “As we celebrate our 25th anniversary this year, our hearts are filled with gratitude for the exceptional relationships we have with clients, partners and regulatory authorities,” says Picard.
  • SPharm is a Canadian consulting firm specialized in  strategic regulatory affairs, development, and approval services for health products (including drugs and medical devices).